Arrhinia-choanal atresia-microphthalmia syndrome is a very rare genetic condition that affects the nose, breathing passages, and eyes. Babies are typically born without an external nose or with blocked nasal airways, and many have small eyes and vision differences. Breathing and feeding problems start at birth and can be severe, but urgent airway support and surgery help many newborns stabilize. Ongoing care often includes staged reconstructive surgeries, vision support, and therapies, and long-term outcomes vary by severity. Not everyone will have the same experience, and with specialized care some children grow and develop, though risks are highest in the newborn period.
Overview
Arrhinia-choanal atresia-microphthalmia syndromeSymptoms
Arrhinia-choanal atresia-microphthalmia syndrome features are usually recognized at birth. These include missing or underdeveloped nose, blocked nasal passages, and small eyes with vision problems. Newborns may have breathing and feeding difficulties, facial differences, and sometimes hormonal or growth issues.
Outlook and prognosis
Many living with Arrhinia-choanal atresia-microphthalmia syndrome can do well with early airway surgery, careful eye and vision support, and coordinated specialty care. Breathing and feeding stabilize first; vision and developmental needs guide longer-term plans. Lifespan varies, but close follow-up improves comfort, safety, and independence.
Causes and risk factors
Arrhinia-choanal atresia-microphthalmia syndrome usually stems from a genetic mutation affecting early facial development, often new and not inherited. A family history can raise risk. No consistent environmental, pregnancy, or lifestyle risk factors have been proven.
Genetic influences
Genetics play a central role in Arrhinia-choanal atresia-microphthalmia syndrome, with most cases linked to changes in the SMCHD1 gene. These variations can disrupt early facial and eye development. Inheritance can be variable; some cases are new (de novo), others familial.
Diagnosis
Doctors recognize it from clinical features at birth, then confirm with nasal endoscopy and CT/MRI of the face and airway. Genetic diagnosis of Arrhinia-choanal atresia-microphthalmia syndrome may involve panel or exome testing and ophthalmologic evaluation.
Treatment and drugs
Treatment for Arrhinia-choanal atresia-microphthalmia syndrome focuses on breathing, feeding, and eye care. Teams plan staged surgeries to open nasal passages, support the airway, and reconstruct facial structures, with vision assessment and prosthetic or protective options. Ongoing therapies help feeding, speech, and development.
Symptoms
People with Arrhinia-choanal atresia-microphthalmia syndrome are born with differences that affect the nose, the back of the nasal passages, and the eyes. Early features of Arrhinia-choanal atresia-microphthalmia syndrome often include an absent or very small nose, blockage at the back of the nose (choanal atresia), and small or missing eyes (microphthalmia or anophthalmia). These differences can affect breathing, feeding in newborns, smell, and vision. Features vary from person to person and can change over time.
The nose may be missing or underdeveloped (arrhinia), giving the face a flatter profile. In Arrhinia-choanal atresia-microphthalmia syndrome, airflow through the front of the nose is reduced or absent, so people breathe mainly through the mouth. This can make air feel dry or cool when breathing.
The back of the nasal passages can be closed (choanal atresia), partially or completely. In newborns, this can cause noisy breathing or a brief bluish tinge that eases when crying. Feeds may be hard to coordinate because stopping to breathe is often needed.
One or both eyes may be small (microphthalmia) or absent (anophthalmia). Vision can range from reduced clarity to little or no light perception. In Arrhinia-choanal atresia-microphthalmia syndrome, the appearance of the eyes and eyelids may also differ.
Because babies usually breathe through the nose, blockage can make feeding tiring. Caregivers may notice slow weight gain or frequent pauses to catch breath during bottle or breast feeds. Feeds may take longer than expected.
How people usually first notice Arrhinia-choanal atresia-microphthalmia syndrome?
Families often notice the first signs of Arrhinia–choanal atresia–microphthalmia syndrome at birth, when a newborn has no visible nose or very underdeveloped nasal structures and struggles to breathe through the nose, especially during feeding. Doctors may also detect choanal atresia (blocked back-of-the-nose passages) causing noisy breathing, cyanosis (bluish color), or the need for mouth breathing or airway support, along with very small eyes (microphthalmia) or eye abnormalities seen on exam. In many cases, how Arrhinia–choanal atresia–microphthalmia syndrome is first noticed includes prenatal ultrasound flags such as absent external nasal structures or eye differences, which prompt detailed newborn evaluation right after delivery.
Types of Arrhinia-choanal atresia-microphthalmia syndrome
Arrhinia-choanal atresia-microphthalmia syndrome is a very rare genetic condition. Based on case reports, differences between people largely relate to which facial and airway structures are involved and how severely, along with eye development and smell function. Not everyone will experience every type. When people talk about types of Arrhinia-choanal atresia-microphthalmia syndrome, they’re usually describing recognizable clinical variants rather than separate diseases, so “types of Arrhinia-choanal atresia-microphthalmia syndrome” reflects patterns seen in the nose, airway, and eyes.
Complete arrhinia
The external nose is absent and nasal passages are not formed, often leading to immediate breathing and feeding challenges after birth. Eye findings can range from small eyes to near-normal size, and smell is typically absent.
Partial arrhinia
Parts of the external nose or nasal passages form but are underdeveloped, so breathing through the nose is limited and congestion-like symptoms are common. Eye size and structure may be closer to typical, and some may retain limited smell.
Bilateral choanal atresia
The back of both nasal passages is blocked by bone or tissue, causing newborns to struggle with airflow until an oral airway or surgery opens the passages. The outer nose may be present or underdeveloped, and smell is usually reduced or absent.
Unilateral choanal atresia
One nasal passage is blocked while the other remains open, so breathing difficulty may be milder and noticed later. People may have persistent one-sided nasal blockage and mouth-breathing, with smell partly preserved.
Severe microphthalmia
One or both eyes are very small, often with significant vision impairment or blindness. Facial features and nasal structures may be more affected, and early vision supports are important.
Mild microphthalmia
Eyes are slightly small with variable vision, sometimes correctable with lenses or low-vision aids. Other facial and nasal differences may be less marked compared with severe forms.
Anosmia predominant
Loss of smell is a main feature, sometimes noticed when people cannot detect food aromas or smoke. Breathing and eye differences may be milder in this variant.
Mixed craniofacial variant
Nose, choanae, and eye development differences occur together in varying degrees, leading to a blended picture across features. The balance of symptoms can shift over time.
What genetics can tell you about symptoms
Variants in the SMCHD1 gene can disrupt early facial and eye development, leading to absent nose (arrhinia), blocked back of the nasal passages (choanal atresia), and small eyes (microphthalmia). These changes reflect how the gene’s “dimmer switch” control of embryonic growth is turned down.
Causes and risk factors
Most cases are caused by a change in the SMCHD1 gene that affects facial and eye development before birth. These changes often arise for the first time in the child, and they can sometimes be inherited from a parent. A known family history raises the chance of arrhinia-choanal atresia-microphthalmia syndrome, but many families have no prior cases. Having a gene change doesn’t mean you’ll definitely develop the condition. Lifestyle, diet, and common environmental exposures are not proven causes, and genetic counseling and genetic testing for arrhinia-choanal atresia-microphthalmia syndrome can help clarify future pregnancy risks.
Environmental and biological risk factors
Arrhinia-choanal atresia-microphthalmia syndrome is present from birth, so any risks act during the earliest weeks of pregnancy when the face and eyes form. Being exposed to risks in your body or environment doesn’t mean illness is inevitable. Many pregnancies affected by this rare pattern occur with no known cause, but certain biological conditions and exposures are linked to higher risk. Below are environmental and biological risk factors for Arrhinia-choanal atresia-microphthalmia syndrome that clinicians watch for in early pregnancy.
Infections like rubella, cytomegalovirus, toxoplasmosis, or Zika in early pregnancy can disrupt facial and eye formation. Risk is greatest when infection happens in the first 8–10 weeks. Prevention through vaccination or avoiding exposure can lower this risk.
Retinoid medicines for acne or psoriasis can cause severe eye and facial differences if taken around conception or in the first trimester. Examples include isotretinoin and acitretin. Even short exposures can have effects.
Methimazole or carbimazole use in early pregnancy has been linked to choanal atresia and other facial differences. Risk appears higher with exposure during the first trimester. Alternative management plans are often considered before conception.
Poorly controlled preexisting diabetes at conception raises the chance of major birth defects, including midface and eye abnormalities. The higher the blood sugar early in pregnancy, the greater the risk.
Genetic risk factors
Genetically, Arrhinia-choanal atresia-microphthalmia syndrome is most often linked to changes in the SMCHD1 gene, which helps control how other genes switch on and off during early development. Many changes arise for the first time in a child, while some are inherited. These findings can’t reliably predict the early symptoms of Arrhinia-choanal atresia-microphthalmia syndrome, because the same change can lead to different features even within one family. Risk is not destiny—it varies widely between individuals.
SMCHD1 changes: Changes in the SMCHD1 gene are the main known genetic cause of Arrhinia-choanal atresia-microphthalmia syndrome. This gene helps regulate other genes during early face and eye development. Different types of changes in SMCHD1 can lead to different effects.
Autosomal dominant: When inherited, one changed copy of SMCHD1 is enough to increase risk. A parent with the same change has a 50% chance to pass it to each child. Features can still differ between relatives.
De novo changes: In many families, the SMCHD1 change occurs for the first time in the child. Parents typically do not have the change on standard blood testing. Sibling risk is usually low.
Parental mosaicism: Rarely, a parent may carry the change in some egg or sperm cells but not in blood. This can slightly raise recurrence risk even if parental tests look negative. A genetics team can discuss whether targeted testing is useful.
Variable expression: The same SMCHD1 change can cause different features, from milder nasal differences to more complex signs of Arrhinia-choanal atresia-microphthalmia syndrome. Some relatives may have subtle or no obvious features. This variability limits how precisely genetics can predict severity.
Gene overlap: SMCHD1 is also involved in a form of muscular dystrophy called FSHD type 2 through a different mechanism. Having an SMCHD1 change linked to Arrhinia-choanal atresia-microphthalmia syndrome does not by itself cause FSHD. Knowing the exact variant helps guide counseling.
Cause not found: A small number of people with Arrhinia-choanal atresia-microphthalmia syndrome have no identifiable SMCHD1 change on current testing. Other genes or mechanisms may be involved but are not yet well understood. Research is ongoing to clarify these rare causes.
Genetic testing: Sequencing of SMCHD1 and related analyses can confirm the cause and clarify family risk. Testing parents helps distinguish inherited from de novo cases. Results can inform discussions about future pregnancies.
Lifestyle risk factors
This is a congenital condition; lifestyle habits do not cause it, but they can influence breathing comfort, feeding and growth, sleep quality, eye safety, and recovery after procedures. The lifestyle risk factors for Arrhinia-choanal atresia-microphthalmia syndrome center on nutrition, airway routines, activity, and sleep. Small daily choices can either reduce airway strain and infection risk or make symptoms harder to manage. Plans should be tailored with the care team to account for surgeries and age.
Inadequate fluid intake and low humidity thicken secretions and increase work of breathing after choanal repair or with small airways. Regular hydration and prescribed humidification keep mucus looser and make suctioning more effective.
Skipping home suctioning, saline, or nebulizer treatments allows crusting and mucus plugging that can obstruct repaired passages. Consistent routines maintain patency and reduce episodes of respiratory distress.
Irregular meals and low-calorie density worsen poor weight gain tied to feeding challenges and oral-motor differences. Nutrient-dense, frequent feeds and dietitian-guided textures support growth and post-surgical healing.
Unmanaged acid reflux can increase airway swelling and aspiration risk, aggravating cough and congestion. Avoiding trigger foods, using smaller meals, and staying upright after feeds may reduce symptoms and night awakenings.
Risk prevention
For Arrhinia-choanal atresia-microphthalmia syndrome, there isn’t a way to prevent the condition itself because it develops before birth. Care focuses on planning ahead and lowering risks tied to breathing, feeding, and eye health. Some prevention is universal, others are tailored to people with specific risks. Prenatal planning and early, coordinated care can reduce complications, even when prenatal signs of Arrhinia-choanal atresia-microphthalmia syndrome are subtle.
A genetics visit can review family history and discuss known gene changes linked to this syndrome. If a family variant is identified, options like preimplantation or prenatal testing can be considered.
Detailed ultrasound and, when needed, fetal MRI can help spot facial and airway differences before birth. Planning delivery at a center with neonatal intensive care and airway specialists reduces emergencies.
Because arrhinia and choanal atresia can block normal breathing, having an airway plan ready at birth is crucial. Delivery room teams can prepare oral airways, breathing support, or urgent procedures if needed.
Facial and airway differences can make latching and coordination hard. Early involvement of feeding and speech therapists helps protect nutrition and lowers the risk of aspiration.
Transmission
Arrhinia-choanal atresia-microphthalmia syndrome is present from birth and is not contagious, so it does not spread through contact, coughing, or blood. In most families, it occurs for the first time because of a new gene change that arises in the egg or sperm. Less often, genetic transmission of arrhinia-choanal atresia-microphthalmia syndrome follows an autosomal dominant pattern: if a parent carries the causative change, each child has a 50% (1 in 2) chance of inheriting it, and features can vary in severity. Genetic counseling and, when available, testing can explain how arrhinia-choanal atresia-microphthalmia syndrome is inherited in your family and help estimate the chance of it happening again.
When to test your genes
Consider genetic testing if you or your child has features like absent or underdeveloped nose (arrhinia), blocked nasal passages (choanal atresia), small eyes (microphthalmia), or similar findings in close relatives. Testing can confirm the diagnosis, guide airway, eye, and surgical planning, and inform recurrence risk for future pregnancies. A genetics team can also coordinate targeted gene panels or exome testing and offer counseling.
Diagnosis
Arrhinia-choanal atresia-microphthalmia syndrome is usually recognized early because breathing and feeding can be hard right after birth and the outside of the nose may be missing or very small. Getting a diagnosis is often a turning point toward answers and support. Doctors look first at the visible features, then confirm details with targeted tests and scans.
Doctors look for absent or underdeveloped nasal structures, blockage at the back of the nose, and unusually small eyes. These clinical features raise strong suspicion for the syndrome.
Teams assess breathing comfort, oxygen levels, and ability to feed safely. This guides immediate support and helps set the urgency for further testing and treatment.
A tiny camera is used to look inside the nasal passages and the openings at the back of the nose. It helps confirm choanal atresia and shows how the nasal cavity is formed.
CT or MRI of the head and face maps the nasal bones, nasal cavity, choanae, and the eye sockets. These imaging findings confirm anatomy, show the extent of blockage, and help plan surgery.
Stages of Arrhinia-choanal atresia-microphthalmia syndrome
Arrhinia-choanal atresia-microphthalmia syndrome does not have defined progression stages. It is present from birth, so the facial and airway differences don’t typically worsen in a step-by-step way, though care needs may shift as a child grows. Diagnosis relies on what’s seen and measured early on—breathing and feeding difficulties right after birth, close examination of the nose and mouth, imaging scans of the face and airways, and eye assessments; early symptoms of Arrhinia-choanal atresia-microphthalmia syndrome often include noisy breathing and trouble feeding. Genetic testing may be offered to clarify certain risks.
Outlook and prognosis
Looking ahead can feel daunting, but many children with Arrhinia-choanal atresia-microphthalmia syndrome can grow and learn with the right care. The earliest phase is usually the most critical because babies may have serious breathing and feeding difficulties due to blocked nasal passages and absent nose structures. Early care can make a real difference, including airway support, surgeries to open the back of the nose, and feeding plans to support growth. Eye findings and vision can vary; some children have very limited vision, while others see enough for day-to-day navigation with supports.
Here’s what research and experience suggest about the future. Survival is most closely linked to how well the airway is managed in infancy and whether there are additional heart, brain, or other organ differences. If early symptoms of Arrhinia-choanal atresia-microphthalmia syndrome are stabilized—especially breathing—many children live into childhood and beyond, attend school, and participate in family life. Developmental progress can be uneven; speech may be delayed due to anatomy and hearing issues, and some will need therapies for motor or learning challenges. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle.
Over time, most people find a steady rhythm with coordinated care from ear, nose, and throat specialists, eye care, craniofacial surgeons, and therapists. Reconstructive procedures often occur in stages across childhood and adolescence, and results improve function more than appearance alone. Life expectancy after the high-risk newborn period is influenced by the severity of associated conditions, but for those without major life-limiting complications, long-term survival is possible. Talk with your doctor about what your personal outlook might look like, including plans for surgeries, vision support, and ways to monitor breathing as your child grows.
Long-term effects
Arrhinia-choanal atresia-microphthalmia syndrome can have lifelong effects that touch breathing, vision, hormone function, and facial growth. Early symptoms of Arrhinia-choanal atresia-microphthalmia syndrome often center on breathing and feeding in infancy, while later features may relate to voice quality, puberty, and daily comfort. Long-term effects vary widely, and not everyone will experience the same challenges. Outlook usually depends on the degree of airway narrowing, eye development, and hormone differences rather than any single feature.
Narrow or altered nasal passages can make airflow less efficient. Mouth breathing may remain common, especially during exertion or colds.
Reduced nasal airflow can raise the risk of snoring or sleep-disordered breathing. This may become more noticeable during growth spurts or weight changes.
Many people have little or no sense of smell (anosmia). This can also blunt the flavor of foods because much of taste depends on smell.
Microphthalmia can lead to reduced vision or blindness in one or both eyes. Depth perception and reading endurance may be affected over time.
How is it to live with Arrhinia-choanal atresia-microphthalmia syndrome?
Living with Arrhinia–choanal atresia–microphthalmia syndrome often means navigating breathing support from infancy, surgeries to open or bypass blocked nasal passages, and adaptations for feeding, speech, and vision, with frequent visits to ear, nose, throat, eye, and craniofacial specialists. Day to day, many rely on alternative airway strategies during colds, use humidification and careful suctioning, and incorporate vision supports and speech therapy, while planning extra time for care routines. Families and caregivers become skilled partners in medical care, coordinating appointments and monitoring for infections or airway challenges, and friends, teachers, and employers may help by offering flexible schedules, accessible environments, and clear communication. With a coordinated care team and the right tools, many build active, connected lives, balancing medical needs with school, work, and relationships.
Treatment and drugs
Treatment for Arrhinia-choanal atresia-microphthalmia syndrome focuses on helping breathing, feeding, vision, and facial growth, usually starting soon after birth and continuing through childhood. Many children need surgery to open the blocked back of the nose (choanal atresia repair) and to create or widen nasal passages so they can breathe through the nose, along with feeding support such as special bottles or a temporary feeding tube. Eye care aims to protect and support vision in small or underdeveloped eyes, with glasses, patching, or surgery when helpful, and regular checks with a pediatric eye specialist. Additional procedures, such as reconstructive surgery of the nose and midface, orthodontic care, and speech therapy, are planned over time by a team that often includes ENT, plastic surgery, ophthalmology, genetics, and nutrition. Supportive care can make a real difference in how you feel day to day, and your doctor may suggest therapies like saline nasal care, humidification, and treatment for reflux to reduce airway irritation and improve comfort.
Non-drug treatment
Care focuses on safe breathing, feeding, vision support, and long-term development. Alongside medicines, non-drug therapies often guide day-to-day care from the newborn period through childhood. Families often seek care soon after birth when early symptoms of Arrhinia-choanal atresia-microphthalmia syndrome affect breathing and feeding. Treatments are tailored to age and specific features.
Positioning, humidified air, and oral airways can help keep breathing passages open. Some infants use CPAP or similar supports, especially during sleep. Care teams watch oxygen levels and adjust support as a child grows.
A feeding specialist can teach pacing, nipple selection, and positioning to improve swallow safety. If weight gain is hard, short-term tube feeding may bridge nutrition needs. Training aims to build safe, comfortable feeding over time.
Surgery can open blocked back-of-nose passages to restore airflow through the nose. Aftercare may include gentle suction, saline rinses, and short-term stents. Breathing patterns and sleep often improve as healing progresses.
Staged procedures can create or reconstruct nasal structures to improve breathing and facial balance. Timing is planned to match growth and development. Teams review risks, benefits, and expected recovery for Arrhinia-choanal atresia-microphthalmia syndrome.
Your genes may have an impact on how drugs work for you
Medicines for arrhinia–choanal atresia–microphthalmia syndrome can work differently based on your genes, which influence how fast you process drugs and how sensitive tissues are to them. Pharmacogenetic testing, when available, may guide safer anesthesia, dosing, and side‑effect prevention.
Pharmacological treatments
Medicines in this condition focus on comfort, hormone support, infection control, and recovery around surgeries. They do not change early symptoms of Arrhinia-choanal atresia-microphthalmia syndrome, but they can ease day-to-day issues like dry eyes, pain, and feeding-related reflux. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy). Your team will individualize choices based on age, goals (like puberty or fertility), and any surgeries planned.
Estradiol or testosterone can be used to induce puberty gradually when natural hormones are low. For those who menstruate, a progestin such as progesterone or medroxyprogesterone is added later to protect the uterus.
Gonadorelin (pulsatile GnRH) can help trigger the body’s own hormone production when the pituitary–gonadal axis needs a jump-start. This is typically managed by specialists and adjusted over time.
Injectable gonadotropins such as FSH (follitropin alfa), LH (lutropin alfa), hMG, or hCG can help achieve ovulation or support sperm production. These therapies require close monitoring to balance effectiveness and safety.
Preservative-free artificial tears like carboxymethylcellulose or hypromellose, and petrolatum-based ointments at night, protect the eye surface in microphthalmia. This can reduce dryness, irritation, and infection risk.
Genetic influences
Research points to single-gene changes that disrupt very early development of the nose, airway, and eyes. In Arrhinia-choanal atresia-microphthalmia syndrome, the gene most often linked is called SMCHD1, though not every person has a detectable change and other genes may be involved. Having a gene change doesn’t always mean you will develop the condition. Many cases happen for the first time in a family (a new, or “de novo,” change), but sometimes a single altered copy from a parent can be enough to cause features, and the severity can vary widely even among relatives. Families often ask whether arrhinia-choanal atresia-microphthalmia syndrome is inherited; genetic testing can help clarify this and may guide planning for future pregnancies. Genetic testing for arrhinia-choanal atresia-microphthalmia syndrome typically focuses on sequencing SMCHD1 and related genes, and your care team may suggest meeting with a genetic counselor to interpret results and discuss family risks.
Is Arrhinia-choanal atresia-microphthalmia syndrome genetic?
Genetics play a central role in Arrhinia-choanal atresia-microphthalmia syndrome, with most cases linked to changes in the SMCHD1 gene. These variations can disrupt early facial and eye development. Inheritance can be variable; some cases are new (de novo), others familial.
Pharmacogenetics—how genetics influence drug effects
People living with Arrhinia-choanal atresia-microphthalmia syndrome often need surgeries, anesthesia, pain control, antibiotics, and sometimes hormone therapy over time, so medicine choices focus on safety and comfort rather than changing the underlying gene change. Genes can influence how quickly you clear certain pain medicines (such as codeine or tramadol) and some sedatives, which can affect how strong they feel and how long they last. For example, people who break down codeine very fast can have stronger effects and side effects, while those who break it down slowly may get little relief; in both cases, the team may choose different pain medicines, like morphine or non-opioid options. Rare inherited enzyme differences can also affect specific operating-room drugs, such as a long-lasting effect from the muscle relaxant succinylcholine, so it’s helpful to share any family history of anesthesia problems. At this time, there aren’t syndrome-specific pharmacogenetic guidelines for Arrhinia-choanal atresia-microphthalmia syndrome, and testing won’t change the early symptoms of Arrhinia-choanal atresia-microphthalmia syndrome, but results can still guide safer, more effective plans for anesthesia and pain control. Decisions about medicines also depend on age, airway anatomy, other health conditions, and how you respond in real life, while hormone therapies are typically adjusted using blood tests and clinical response rather than genetic results.
Interactions with other conditions
Because the nasal passages are underdeveloped or blocked, respiratory infections like colds, RSV, or the flu can trigger more severe breathing problems than usual and may increase the chance of hospital care. A condition may “exacerbate” (make worse) symptoms of another. Reflux, feeding difficulties, and sleep apnea can feed into one another as well—stomach contents moving upward can irritate the airway, worsen nighttime breathing, and raise the risk of aspiration pneumonia. Some people with Arrhinia-choanal atresia-microphthalmia syndrome also have hormone differences that delay puberty or affect fertility, so working with an endocrinology team matters for bone health and growth alongside any other long-term illness. Vision impairment from eye malformations can combine with prematurity or neurologic conditions to complicate development, learning, and mobility, so early low-vision support helps. Families sometimes first notice early symptoms of Arrhinia-choanal atresia-microphthalmia syndrome during a viral cold, when feeding and breathing become especially difficult, and future procedures or anesthesia should be planned carefully since airway differences can make sedation and intubation more challenging.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described infants born with very small eyes, narrow or blocked nasal passages, and difficulty breathing soon after birth. Families and midwives noticed that some newborns could not pass air through the nose, especially when feeding or sleeping, and that their eyes looked unusually small. In some cases, the tip of the nose seemed flat or underdeveloped. These early notes captured day-to-day struggles—trouble latching, noisy breathing, pauses during sleep—even when the exact pattern wasn’t yet recognized.
First described in the medical literature as a cluster of features—absent or tiny nasal structures (arrhinia), blockage at the back of the nose (choanal atresia), and small eyes (microphthalmia)—the condition gradually gained definition as doctors compared case reports from different hospitals and countries. From these first observations, clinicians recognized that the combination was more than chance. Careful drawings, early photographs, and later X‑rays helped confirm that the nose and eye changes tended to occur together, along with breathing difficulties present from birth.
As medical science evolved, anesthesia and airway care improved survival for newborns with severe nasal blockage, allowing doctors to follow children over time and describe additional features. Surgeons documented how opening the back of the nose could ease feeding and sleep, and how staged procedures on the nose and eyelids might support both breathing and vision protection. With each decade, imaging moved from simple head films to CT and MRI, showing how the nasal passages and eye sockets formed before birth. This gave specialists a clearer picture of the structures involved in Arrhinia‑choanal atresia‑microphthalmia syndrome and helped them plan safer operations.
Advances in genetics later added another layer. Researchers reported families in which more than one child was affected and began studying genes active during early face and eye development. While the genetic causes can vary and remain incompletely understood for some, these studies explained why features may range from mild nasal narrowing to near‑complete absence of nasal passages, and from slightly small eyes to severely reduced eye size.
Over time, descriptions became more consistent, and the name Arrhinia‑choanal atresia‑microphthalmia syndrome helped clinicians and families find one another, share experiences, and guide care. Despite evolving definitions, the focus has remained the same: recognizing early symptoms of Arrhinia‑choanal atresia‑microphthalmia syndrome—especially breathing and feeding difficulties—so babies receive prompt, coordinated support. Knowing the condition’s history shows how bedside observation, surgical innovation, and genetic research each contributed to the care pathways used today.